News Articles Tagged: ARN-810

The Role of GDC-0810 in Clinical Trials for ER+ Breast Cancer

An overview of the ongoing GDC-0810 (ARN-810) clinical trials and their significance for treating ER+ breast cancer, particularly in resistant cases.

Exploring the Efficacy of ARN-810 in Tamoxifen-Resistant Breast Cancer Models

Investigate how ARN-810 (GDC-0810), an oral SERD, demonstrates potent efficacy in overcoming tamoxifen resistance in breast cancer models.